Arcutis Biotherapeutics (ARQT) opened Q1 2026 with total revenue of US$105.4 million, basic EPS of a US$0.09 loss, and a net income loss of US$11.3 million, while its trailing twelve month revenue stood at US$415.6 million and basic EPS at a US$0.02 loss. Over recent quarters, the company reported revenue moving from US$71.4 million in Q4 2024 to US$129.5 million in Q4 2025, with quarterly basic EPS shifting between a loss of US$0.20 in Q1 2025 and a profit of US$0.14 in Q4 2025. For investors, the combination of higher revenue, improving trailing twelve month EPS, and still negative quarterly earnings highlights the importance of how quickly margins may firm up from here.

See our full analysis for Arcutis Biotherapeutics.

With the latest figures on the table, the next step is to see how these results line up with the main narratives around Arcutis's growth prospects and risk profile, and where the numbers start to challenge those stories.

Trailing 12‑month loss narrows to US$2.4 million

• On a trailing 12‑month basis, net loss moved from US$140.0 million in Q4 2024 to US$2.4 million in Q1 2026, while revenue over that same window rose from US$196.5 million to US$415.6 million.
• Consensus narrative sees ZORYVE expansion and broader insurance coverage as key to sustaining revenue growth, and this tightening loss profile sits alongside that view, yet:
  • Trailing 12‑month basic EPS went from a loss of US$1.16 per share in Q4 2024 to a much smaller loss of US$0.02 per share in Q1 2026, which fits the idea of improving operating leverage but still leaves the company unprofitable.
  • Analysts also expect revenue to grow 18.9% per year with earnings growth of 49.11% per year and a path to profitability within three years, so the current small loss keeps attention on how quickly that shift actually shows up in future reported numbers.

Quarterly earnings swing between profit and loss

• Over the last five reported quarters, Arcutis moved from a net loss of US$25.1 million and a basic EPS loss of US$0.20 in Q1 2025 to a profit of US$17.4 million and basic EPS of US$0.14 in Q4 2025, then back to a net loss of US$11.3 million and a basic EPS loss of US$0.09 in Q1 2026.
• Bears focus on this dependence on ZORYVE and high spending, and the earnings swing gives that cautious view some grounding, because:
  • The move from a quarterly profit in Q4 2025 to a loss in Q1 2026 shows that profitability is not yet consistent, which links directly to concerns about heavy R&D and SG&A potentially keeping operating results volatile.
  • The bearish narrative also points to concentration risk in a single franchise and limited pipeline, so these uneven quarterly profits and losses keep the spotlight on how much of the bottom line is tied to a few revenue drivers.

Skeptics warn that this back and forth between positive and negative earnings could persist while spending and product concentration remain high, so it helps to see how that risk is framed in the full bearish narrative.🐻 Arcutis Biotherapeutics Bear Case

Valuation gap vs DCF and target price

• With the stock at US$20.66, the supplied data show a DCF fair value of US$81.45 and an analyst consensus price target of US$34.63, alongside a P/S of 6.2x compared with peer and US Biotechs averages of 8.9x and 10.9x.
• Supporters argue this discount lines up with a bullish thesis built on higher growth forecasts, and the valuation data connect to that by:
  • Highlighting that the share price sits well below both the DCF fair value and the analyst target, while analysts in the dataset see a 67.6% implied upside from the current US$20.66 level.
  • Showing that the P/S multiple is lower than both peer and broader biotech averages, which ties into the view that the market is pricing in ongoing losses even as the trailing 12‑month net loss has compressed to US$2.4 million.

If you are weighing whether those growth expectations justify the gap between price, DCF fair value and analyst target, it can help to see how bullish investors are connecting these valuation numbers to the wider story.🐂 Arcutis Biotherapeutics Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Arcutis Biotherapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this combination of tightening losses, valuation gaps, and shifting earnings leaves you uncertain, use it as a prompt to check the data yourself and decide where you stand. Then round out your view with the 5 key rewards and 1 important warning sign.

See What Else Is Out There

Arcutis is still reporting losses, showing uneven quarterly earnings and heavy spending tied to a concentrated product lineup, which keeps overall risk elevated for shareholders.

If that earnings volatility and product concentration feels uncomfortable, compare it with companies that score better on stability and downside protection by scanning the 72 resilient stocks with low risk scores today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.